Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Plateletpheresis Stories

2008-12-06 10:00:00

PHILADELPHIA, Dec. 6 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced positive safety and efficacy results from RAISE (RAndomized placebo- controlled ITP Study with Eltrombopag), a Phase III study of PROMACTA(R) (eltrombopag) in adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who had received one or more prior ITP therapies. Patients receiving PROMACTA were eight times more likely than those on placebo to maintain platelet counts between 50,000 to...

2008-12-04 09:29:00

People with Rare Anemias, Blood Cancers Need You NEW YORK, Dec. 4 /PRNewswire-USNewswire/ -- As winter holidays fast approach, New York Blood Center (NYBC) calls upon the community to please set aside a time to donate blood. The holidays are a time when blood supply decreases while emergency needs remain the same. It is also a time when it becomes more difficult to find precise blood matches for those that are very sick. December is also Aplastic Anemia Awareness Month. Aplastic anemia...

2008-09-03 18:00:41

MEDIA ADVISORY: WHAT: Officials from the U.S. Food and Drug Administration Blood Products Advisory Committee (BPAC) will meet with government institutions and top experts from academia and private industry on September 10, 11 and 12 in two separate meetings to address issues related to safety of the blood supply including: -- Bacterial contamination of donated blood products for transfusion which can lead to sepsis (Sept. 10) -- Risk of infectious disease such as malaria from blood...

2008-08-30 09:01:03

By Risha Chitlangia New Delhi: Keeping in mind the rising number of dengue cases and the corresponding demand for platelets, the Delhi government is planning to make platelets available free of cost during the dengue season. Health minister Dr Yoganand Shastri has directed the state blood transfusion department to moot a proposal for the same, which sources say has got an in-principle approval. The Delhi government has three centres which have platelet separator machines through which...

2008-08-25 09:00:26

The U.S. Food and Drug Administration says it has approved Nplate (romiplostim), the first product that directly stimulates bone marrow platelet production. The FDA said the new drug will be used to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding. The condition, which usually develops in adults, is known as chronic immune thrombocytopenic purpura, or ITP, a disease that results in a low number of platelets, the blood components that help...

2008-08-22 15:00:51

Amgen Inc. (NASDAQ: AMGN) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura (ITP). Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of...

2008-06-30 15:03:02

On Wednesday, July 2, Stanford Blood Center invites the public to celebrate its 30th anniversary. Palo Alto Mayor Larry Klein will kick off the festivities at noon with a proclamation on behalf of the City of Palo Alto recognizing Stanford Blood Center's dedicated service to the community. Other speakers recognizing the blood center's milestones and contributions will be Edgar Engleman, MD, medical director; Vince Yalon, administrative director; and blood recipient Ron Preston. People...

2008-06-16 09:01:17

Amgen has announced new positive data from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura, a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue immune thrombocytopenic purpura (ITP)...

2008-06-15 06:00:22

Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue ITP...

2008-04-01 03:00:45

By Jason Sheeler, The Dallas Morning News Apr. 1--Loose change is so annoying," I thought, focusing on anything but the present. I lay inert, terrified to move, my body unnaturally reclined at a 45-degree angle in the hospital bed. But my mind raced, keeping pace with the soft-footed ICU nurses attaching sticky pulse-keeping things all over my body. I clamped my eyes shut, every light, noise and heartbeat feeling like a slap to the nickel-size hematoma I woke up with that morning --...